Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.

No abstract is available for this paper.

• Publication year

  2005

• Venue

  European Journal of Pharmacology

• Publication date

  2005-03-07

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/J.EJPHAR.2005.01.018PMID 15740724
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• In Vitro and In Vivo: The Story of Nonoxynol 9

  2005cited by this paper
• Modulation of Serotonergic Function in Rat Brain by VN2222, a Serotonin Reuptake Inhibitor and 5-HT1A Receptor Agonist

  2003cited by this paper
• Effect of chronic fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex

  2002cited by this paper
• In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography.

  2002cited by this paper
• Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist

  2002cited by this paper
• Tandospirone potentiates the fluoxetine-induced increases in extracellular dopamine via 5-HT(1A) receptors in the rat medial frontal cortex.

  2002cited by this paper
• Agonist-Induced Internalization of Serotonin-1A Receptors in the Dorsal Raphe Nucleus (Autoreceptors) But Not Hippocampus (Heteroreceptors)

  2001cited by this paper
• Dopamine D2 Receptor Occupancy Is a Common Mechanism Underlying Animal Models of Antipsychotics and Their Clinical Effects

  2001cited by this paper
• Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study.

  2001cited by this paper
• Inactivation of 5-HT(1A) receptors in hippocampal and cortical homogenates.

  2000influential reference
• Novel radiotracers for imaging the serotonin transporter by positron emission tomography: synthesis, radiosynthesis, and in vitro and ex vivo evaluation of (11)C-labeled 2-(phenylthio)araalkylamines.

  2000cited by this paper
• Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of (11)C-Labeled 2-(Phenylthio)araalkylamines.

  2000cited by this paper
• The role of 5-HT(1A) and 5-HT(1B/1D) receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (+/-)pindolol.

  2000cited by this paper
• Effects of chronic fluoxetine treatment in the presence and absence of (±)pindolol: a microdialysis study

  2000cited by this paper
• Effects of (−)‐tertatolol, (−)‐penbutolol and (±)‐pindolol in combination with paroxetine on presynaptic 5‐HT function: an in vivo microdialysis and electrophysiological study

  1999cited by this paper
• Chronic alnespirone-induced desensitization of somatodendritic 5-HT1A autoreceptors in the rat dorsal raphe nucleus.

  1999cited by this paper
• Role of the medial prefrontal cortex in 5‐HT1A receptor‐induced inhibition of 5‐HT neuronal activity in the rat

  1999cited by this paper
• Buspirone modulates basal and fluoxetine-stimulated dialysate levels of dopamine, noradrenaline and serotonin in the frontal cortex of freely moving rats: activation of serotonin1A receptors and blockade of alpha2-adrenergic receptors underlie its actions.

  1999cited by this paper
• Effects of Acute and Chronic Administration of the Serotonin1A Agonist Buspirone on Serotonin Synthesis in the Rat Brain

  1999cited by this paper
• Postsynaptic 5-HT1A receptors control 5-HT release in the rat medial prefrontal cortex.

  1999cited by this paper
• Role of Somatodendritic 5‐HT Autoreceptors in Modulating 5‐HT Neurotransmission a

  1998cited by this paper
• Effects of 5-HT1A receptor antagonists on fluoxetine-induced changes in extracellular serotonin concentrations in rat frontal cortex.

  1998cited by this paper
• Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release.

  1998cited by this paper
• Preferential Potentiation of the Effects of Serotonin Uptake Inhibitors by 5‐HT1A Receptor Antagonists in the Dorsal Raphe Pathway: Role of Somatodendritic Autoreceptors

  1997cited by this paper
• Potentiation of the Fluoxetine‐Induced Increase in Dialysate Levels of Serotonin (5‐HT) in the Frontal Cortex of Freely Moving Rats by Combined Blockade of 5‐HT1A and 5‐HT1B Receptors with WAY 100,635 and GR 127,935

  1997cited by this paper
• Effect of acute and repeated versus sustained administration of the 5-HT1A receptor agonist ipsapirone: electrophysiological studies in the rat hippocampus and dorsal raphe

  1997cited by this paper
• Buspirone Enhances Duloxetine‐ and Fluoxetine‐Induced Increases in Dialysate Levels of Dopamine and Noradrenaline, but Not Serotonin, in the Frontal Cortex of Freely Moving Rats

  1997cited by this paper
• WAY100635-induced augmentation of the 5-HT-elevating action of citalopram: relative importance of the dose of the 5-HT1A (auto)receptor blocker versus that of the 5-HT reuptake inhibitor.

  1997cited by this paper
• Effect of a selective 5‐HT reuptake inhibitor in combination with 5‐HT1A and 5‐HT1B receptor antagonists on extracellular 5‐HT in rat frontal cortex in vivo

  1997cited by this paper
• EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.

  1997cited by this paper
• Effect of Pindolol on the Function of Pre- and Postsynaptic 5-HT1A Receptors: In Vivo Microdialysis and Electrophysiological Studies in the Rat Brain

  1996cited by this paper
• (-)-Pindolol, but not buspirone, potentiates the citalopram-induced rise in extracellular 5-hydroxytryptamine.

  1996cited by this paper
• 8-OH-DPAT-induced release of hippocampal noradrenaline in vivo: evidence for a role of both 5-HT1A and dopamine D1 receptors.

  1996cited by this paper
• Interaction between a selective 5‐HT1A receptor antagonist and an SSRI in vivo: effects on 5‐HT cell firing and extracellular 5‐HT

  1995influential reference
• Effects of acute fluoxetine on extracellular serotonin levels in the raphe: an in vivo microdialysis study.

  1995cited by this paper
• Monoamine Interactions Measured by Microdialysis in the Ventral Tegmental Area of Rats Treated Systemically with (±)‐8‐Hydroxy‐2‐(Di‐n‐Propylamino)tetralin

  1995cited by this paper
• Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5‐hydroxytryptamine1A receptor activation

  1995cited by this paper
• Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: microdialysis studies in the awake and anaesthetized rat.

  1994cited by this paper
• Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex.

  1992cited by this paper
• Modification of 5‐HT neuron properties by sustained administration of the 5‐HT1A agonist gepirone: Electrophysiological studies in the rat brain

  1987cited by this paper
• The Rat Brain in Stereotaxic Coordinates

  1983cited by this paper

• Serotonin-dopamine interactions in psychostimulant-induced gene regulation: SSRI antidepressants potentiate gene regulation by methylphenidate (Ritalin) in the striatum and enhance behavioral profile indicative of addiction liability in rodents.

  2025cites this paper
• Discovery of a Novel Multitarget Analgesic Through an In Vivo-Guided Approach

  2025cites this paper
• Long-term neuronal and neurocognitive consequences in offspring after prenatal exposure to a novel antidepressant, vilazodone: Role of BDNF/Bax-Bcl-2/AChE mediated pathways.

  2025cites this paper
• Serotonin Receptors in Areas of the Emotion Regulation Network in Human and Rat Brains—A Comparative Autoradiographic Study

  2025cites this paper
• (-)-Syringaresinol Exerts an Antidepressant-like Activity in Mice by Noncompetitive Inhibition of the Serotonin Transporter

  2024cites this paper
• Structural pharmacology and therapeutic potential of 5-methoxytryptamines

  2024cites this paper
• Synthesis and biological evaluation of multimodal monoaminergic arylpiperazine derivatives with potential antidepressant profile.

  2024cites this paper
• Therapeutic Approaches for Treatment and Management of Depressive Disorder: A Comprehensive Review

  2024cites this paper
• Vilazodone, a Novel SSRI Antidepressant with 5-HT1A Partial Agonist Properties: Diminished Potentiation of Chronic Oral Methylphenidate-Induced Dynorphin Expression in the Striatum in Adolescent Male Rats

  2024cites this paper
• Unveiling behavioral and molecular neuroadaptations related to the antidepressant action of cannabidiol in the unpredictable chronic mild stress model

  2023cites this paper
• Vilazodone, a Selective Serotonin Reuptake Inhibitor with Diminished Impact on Methylphenidate-Induced Gene Regulation in the Striatum: Role of 5-HT1A Receptor

  2023cites this paper
• The effects of Vilazodone, YL-0919 and Vortioxetine in hemiparkinsonian rats

  2022cites this paper
• Sexual dysfunction with major depressive disorder and antidepressant treatments: impact, assessment, and management

  2022cites this paper
• Vilazodone for Major Depression in Adults: Pharmacological Profile and an Updated Review for Clinical Practice

  2022cites this paper
• The clinical utility of newer antidepressant agents: Understanding the role in management of MDD

  2022cites this paper
• NDT_A_279342 1175..1193

  2022cites this paper
• Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease

  2021cites this paper
• The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter

  2021cites this paper
• Early response to trazodone once-a-day in major depressive disorder: review of the clinical data and putative mechanism for faster onset of action

  2021cites this paper
• Serotonin/dopamine interaction: Electrophysiological and neurochemical evidence.

  2021cites this paper
• Sexual Motivation in Health and Disease: Focus on Sexual Dysfunctions in Psychiatric Disorders

  2021cites this paper
• Determination and quantitation of benzofuran, Indole and piperazine containing selective serotonin reuptake inhibitor vilazodone hydrochloride in human plasma by LC-ESI-MS/MS with an application to pharmacokinetic study under the frame work of bioequivalence study

  2021cites this paper
• Use of Sertraline in Hemodialysis Patients

  2021cites this paper
• Functional characterization of 5-HT1A and 5-HT1B serotonin receptor signaling through G-protein-activated inwardly rectifying K+ channels in a fluorescence-based membrane potential assay.

  2020cites this paper
• The binding mode of vilazodone in the human serotonin transporter elucidated by ligand docking and molecular dynamics simulations.

  2020cites this paper
• Table of Contents

  2020cites this paper
• Simultaneous determination of some antidepressant drugs and vitamin B12 in pharmaceutical products and urine sample using HPLC method.

  2020cites this paper
• The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease

  2020cites this paper
• Sequential One-Pot Synthesis of 3-Arylbenzofurans from N-Tosylhydrazones and Bromophenol Derivatives.

  2020cites this paper
• A nanoparticle modified carbon paste sensor for electrochemical determination of the antidepressant agent vilazodone

  2019cites this paper
• Novel multitarget 5-arylidenehydantoins with arylpiperazinealkyl fragment: Pharmacological evaluation and investigation of cytotoxicity and metabolic stability.

  2019cites this paper
• Molecular aspects of depression: A review from neurobiology to treatment

  2019cites this paper
• Substrate and inhibitor binding to the serotonin transporter: Insights from computational, crystallographic, and functional studies.

  2019cites this paper
• Current Status of Vilazodone

  2019cites this paper
• New Treatment Options for Depression: A Primer for Internists.

  2019cites this paper
• Behavioral effects of buspirone in a mouse model of posttraumatic stress disorder.

  2019cites this paper
• Pharmacogenomics in Psychiatric Disorders

  2019cites this paper
• Evaluation of vilazodone for the treatment of depressive and anxiety disorders

  2018cites this paper
• Drugs which influence serotonin transporter and serotonergic receptors: Pharmacological and clinical properties in the treatment of depression

  2018cites this paper
• Efficacy and tolerability of different doses of three new antidepressants for treating major depressive disorder: A PRISMA-compliant meta-analysis.

  2018cites this paper
• Zukünftige Therapieansätze der Depressionsbehandlung

  2017cites this paper
• New Trends in Antidepressant Drug Research

  2017cites this paper
• Development and Validation of Vilazodone HCl by RP-HPLC In Bulk and in Pharmaceutical Formulation Along with its Application in Dissolution

  2017cites this paper
• Identification and characterization of vilazodone metabolites in rats and microsomes by ultrahigh-performance liquid chromatography/quadrupole time-of-flight tandem mass spectrometry.

  2017cites this paper
• Exploring the concept of human OCT3 inhibitors as a novel class of antidepressants

  2016influential citation
• A VALIDATED SPECTROPHOTOMETRIC METHOD FOR DETERMINATION OF VILAZODONE HYDROCHLORIDE IN PHARMACEUTICAL DOSAGE FORM

  2016cites this paper
• Vilazodone for major depressive disorder in adults

  2016cites this paper
• The frontal cortex as a network hub controlling mood and cognition: Probing its neurochemical substrates for improved therapy of psychiatric and neurological disorders

  2016cites this paper
• The Preclinical and Clinical Effects of Vilazodone for the Treatment of Major Depressive Disorder

  2016influential citation
• Impact of Depressogenic-and Antidepressant-like Challenges on Monoamine System Activities: in vivo Electrophysiological Characterization Studies

  2016cites this paper
• Vilazodone does not inhibit sexual behavior in male rats in contrast to paroxetine: A role for 5-HT1A receptors?

  2016cites this paper
• UPLC-MS-MS Method for the Determination of Vilazodone in Human Plasma: Application to a Pharmacokinetic Study.

  2016cites this paper
• Differential effects of vilazodone versus citalopram and paroxetine on sexual behaviors and serotonin transporter and receptors in male rats

  2016cites this paper
• Antidepressant Effect And The Possible Mechanism(S) Of Action Of Secondary Metabolites From Trichilia Monadelpha In Murine Models

  2016cites this paper
• Vilazodone for the Treatment of Depression: An Update

  2016cites this paper
• P-glycoprotein differentially affects escitalopram, levomilnacipran, vilazodone and vortioxetine transport at the mouse blood-brain barrier in vivo.

  2016cites this paper
• Tests for Anxiolytic Activity

  2015cites this paper
• Evaluation of the efficacy and safety of vilazodone for treating major depressive disorder

  2015cites this paper
• DSP-1053, a novel serotonin reuptake inhibitor with 5-HT1A partial agonistic activity, displays fast antidepressant effect with minimal undesirable effects in juvenile rats

  2015cites this paper
• Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs.

  2015cites this paper
• Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy

  2015influential citation
• Vilazodone for the Treatment of Major Depressive Disorder: Focusing on Its Clinical Studies and Mechanism of Action

  2015cites this paper
• Criticisms of drugs in early development for the treatment of depression: what can be improved?

  2015cites this paper
• Serotonergic Regulation of Prefrontal Cortical Circuitries Involved in Cognitive Processing: A Review of Individual 5-HT Receptor Mechanisms and Concerted Effects of 5-HT Receptors Exemplified by the Multimodal Antidepressant Vortioxetine.

  2015cites this paper
• Long-term administration of the antidepressant vilazodone modulates rat brain monoaminergic systems.

  2015cites this paper
• Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data.

  2015cites this paper
• Pharmacological Studies of Novel Agents with Serotonergic or Glutamatergic Neuromodulatory Actions Using Mood Disorder Model Animals

  2015cites this paper
• Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder

  2015cites this paper
• Mechanism of action of the SPARI vilazodone: serotonin 1A partial agonist and reuptake inhibitor

  2014cites this paper
• Antidepressant-Induced Sexual Dysfunction: an Updated Review

  2014cites this paper
• A Review of Vilazodone, Serotonin, and Major Depressive Disorder

  2014cites this paper
• Journal of Global Trends in Pharmaceutical Sciences

  2014cites this paper
• DETERMINATION OF VILAZODONE IN PHARMACEUTICAL FORMULATIONS BY HPLC

  2014cites this paper
• Development and validation of spectroscopic methods for the estimation of Dalfampridine in bulk and in tablet formulation

  2014cites this paper
• Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output

  2014cites this paper
• Development and Validation of Spectrofluorimetric and RP-HPLC with Fluorimetric Detection Methods for the Determination of Vilazodone in Bulk and Pharmaceutical Preparation

  2014cites this paper
• Development and Validation of HPTLC/Densitometry Method for the Estimation of Vilazodone HCl in Bulk and in Tablet Formulation

  2014cites this paper
• Development and Validation of Spectroscopic Methods for the Estimation of Vilazodone in Bulk and in Tablet Formulation

  2014cites this paper
• DETERMINATION OF VILAZODONE IN PHARMACEUTICAL FORMULATIONS BY HPLC METHOD

  2014cites this paper
• Vilazodone in the treatment of major depressive disorder: efficacy across symptoms and severity of depression

  2014cites this paper
• A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine

  2014cites this paper
• Original article Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials

  2014cites this paper
• Effects of Acute and Sustained Administration of Vilazodone (EMD68843) on Monoaminergic Systems: An In Vivo Electrophysiological Study

  2014influential citation
• Early and sustained improvement with vilazodone in adult patients with major depressive disorder: post hoc analyses of two phase III trials

  2014cites this paper
• A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy

  2014influential citation
• Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.

  2013cites this paper
• The rapid recovery of 5-HT cell firing induced by the antidepressant vortioxetine involves 5-HT(3) receptor antagonism.

  2013cites this paper
• A review of current evidence for vilazodone in major depressive disorder

  2013cites this paper
• NK1 receptor antagonism lowers occupancy requirement for antidepressant-like effects of SSRIs in the gerbil forced swim test.

  2013cites this paper
• The effect of vilazodone on sexual function during the treatment of major depressive disorder.

  2013cites this paper
• Pharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment

  2013cites this paper
• Vilazodone lacks proarrhythmogenic potential in healthy participants: a thorough ECG study.

  2013cites this paper
• Translation of Central Nervous System Occupancy from Animal Models: Application of Pharmacokinetic/Pharmacodynamic Modeling

  2013cites this paper
• The discovery and development of vilazodone for the treatment of depression: a novel antidepressant or simply another SSRI?

  2013cites this paper
• Synthetic approaches to the 2011 new drugs.

  2013cites this paper
• 19 Neurotransmitter and Behaviour : Serotonin and Anxiety

  2012cites this paper
• METHOD DEVELOPMENT AND VALIDATION FOR THE ASSAY OF VILAZODONE IN BULK AND FORMULATION BY USING RP-HPLC TECHNIQUE

  2012cites this paper
• Presynaptic Selectivity of a Ligand for Serotonin 1A Receptors Revealed by In Vivo PET Assays of Rat Brain

  2012cites this paper
• Original article The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder

  2012cites this paper
• Translatability scoring in drug development: eight case studies

  2012cites this paper